Trial
NCT04955938
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Chicago
Collaborators
—
Condition
IDH Mutation
Intervention
Ivosidenib
Why stopped
unable to accrue
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-31